Alamar Biosciences, Inc. (ALMR) AI Stock Analysis

Company Guidance

Alamar raised full-year 2026 revenue guidance to $121 million to $123 million, representing annual growth of 64% at the midpoint, versus previous guidance of $116 million to $120 million; for Q4, it expects an increase in consumables revenue to offset the decrease expected in TAP, with TAP revenue expected to decline sequentially, operating expenses to increase as certain R&D projects planned for 2027 are pulled forward, and the top end of the range representing a sequential increase from Q3 to Q4. The company expects to place 100 or more instruments this year and maintain pull-through above 400,000 average annual instrument pull-through, expects U.K. Biobank sample processing to begin in Q4 and ramp up in 2027, with that study expected to be complete by the end of 2027, and expects the GSK study to begin in Q1 2027; it is not providing a time line on its completion and is not guiding to projects or samples per quarter. For 2027, Alamar plans to keep expanding its installed base, launch a multiplex panel in a new disease area, submit ARGO HT/DX for FDA marketing authorization by the end of next year and establish partnerships to support its diagnostic strategy.